We have identified eight potent neutralizing antibodies (mAbs) from recovered COVID-19 patients for COVID-19 treatment. These antibodies may be used as pre-exposure prophylaxis, i.e., as short-term protection from infection for populations at risk and highly exposed medical teams or those that did not develop enough antibodies post vaccination
UNMET NEED
The COVID-19 pandemic caused by SARS-CoV-2, has infected over 205 million people worldwide and has killed over 4 million. The virus continues to spread globally causing incomparable economic, social and public health damage.
Currently, while effective vaccines had been developed, it is evident, that vaccines alone are not enough to combat the virus.
OUR SOLUTION
A unique cocktail of neutralizing antibodies isolated from recovered COVID-19 patients. These mAbs exhibit different mechanisms of action, and when mixed into various cocktails inhibit up to 100% of SARS-CoV-2, including its variants, in culture
ADVANTAGES:
• Isolation of antibodies directly from B cells of infected patients and hence expected to be non-toxic with no side effects.
• The antibodies have gone through the natural selection processes and represent the most effective response of the body towards the virus
• Stable, exhibiting an average half-life of 23 days in the human blood
• Possible pre-exposure prophylaxis treatment, i.e., as short-term protection from infection for populations at risk and highly exposed medical teams.
• Effective against the various virus strains (figure D)

STATUS AND NEXT STEPS:
Our aim is to test the new TAU-mAb cocktail in human clinical trials as an to inhibit SARS-CoV-2 and its variants. Due to their complete human origin and nature, these mAbs can also be examined as pre-exposure prophylaxis, i.e., as short-term protection from infection for populations at risk and highly exposed medical teams and those that had not developed immunity post vaccination.